Bortezomib Fresenius Kabi: Uses, Dosage & Side Effects
A proteasome inhibitor used in the treatment of multiple myeloma and mantle cell lymphoma, administered by intravenous or subcutaneous injection
Bortezomib Fresenius Kabi is a proteasome inhibitor used in the treatment of multiple myeloma and mantle cell lymphoma. It works by blocking the 26S proteasome, a cellular complex responsible for breaking down proteins that regulate cell growth, division, and death. By inhibiting this process, bortezomib disrupts the survival mechanisms of cancer cells, particularly myeloma cells that produce large amounts of abnormal proteins. This medication is administered by injection (intravenous or subcutaneous) in a hospital or clinic setting and is available only by prescription. Bortezomib-based regimens have become a cornerstone of multiple myeloma treatment worldwide and have significantly improved survival outcomes for patients with this disease.
Quick Facts: Bortezomib Fresenius Kabi
Key Takeaways
- Bortezomib Fresenius Kabi is a proteasome inhibitor that has become a foundational treatment for multiple myeloma, used in both newly diagnosed and relapsed/refractory disease, as well as for relapsed mantle cell lymphoma.
- The medication can be given subcutaneously or intravenously; the subcutaneous route is preferred in many settings as it offers equivalent efficacy with a significantly lower risk of peripheral neuropathy.
- Peripheral neuropathy and thrombocytopenia are the most clinically significant side effects; both are generally manageable with dose modifications and careful monitoring by your healthcare team.
- Antiviral prophylaxis (such as aciclovir) is strongly recommended during bortezomib treatment due to the increased risk of herpes zoster (shingles) reactivation.
- Treatment is given in cycles (typically twice weekly for two weeks followed by a rest period), and the duration depends on the specific treatment regimen and how well the disease responds.
What Is Bortezomib Fresenius Kabi and What Is It Used For?
Bortezomib Fresenius Kabi contains the active substance bortezomib, a dipeptide boronic acid that acts as a selective, reversible inhibitor of the 26S proteasome. The proteasome is a barrel-shaped multiprotein complex found in all eukaryotic cells that serves as the primary pathway for degrading ubiquitin-tagged intracellular proteins. These proteins include key regulators of cell cycle progression, apoptosis (programmed cell death), transcription factor activation, and DNA repair. By blocking proteasomal activity, bortezomib disrupts multiple cellular processes simultaneously, making it particularly effective against cancer cells that rely heavily on protein homeostasis for survival.
Multiple myeloma cells are exquisitely sensitive to proteasome inhibition because they produce enormous quantities of immunoglobulin proteins (antibodies). This high rate of protein synthesis places exceptional demands on the proteasome to maintain cellular health by removing misfolded and excess proteins. When the proteasome is inhibited by bortezomib, these abnormal proteins accumulate within the cell, triggering endoplasmic reticulum stress, activation of the unfolded protein response, and ultimately apoptosis. Additionally, bortezomib inhibits the activation of nuclear factor-kappa B (NF-kB), a transcription factor that promotes cancer cell survival, proliferation, and resistance to chemotherapy. Inhibition of NF-kB also suppresses the production of growth factors and adhesion molecules in the bone marrow microenvironment that support myeloma cell growth.
Beyond its direct effects on cancer cells, bortezomib has important immunomodulatory properties. It can enhance the susceptibility of cancer cells to recognition and killing by the immune system, and it has anti-angiogenic effects that inhibit the formation of new blood vessels that tumors need to grow. These pleiotropic mechanisms contribute to the remarkable clinical efficacy of bortezomib in the treatment of multiple myeloma and mantle cell lymphoma.
Bortezomib Fresenius Kabi is approved by the European Medicines Agency (EMA) and regulatory authorities in multiple countries for the following therapeutic indications:
- Previously untreated multiple myeloma: In combination with melphalan and prednisone (VMP regimen) for adult patients who are not eligible for high-dose chemotherapy with stem cell transplantation. The landmark VISTA trial demonstrated a significant improvement in time to disease progression and overall survival with the VMP regimen compared to melphalan-prednisone alone.
- Previously untreated multiple myeloma (transplant-eligible): In combination with dexamethasone, or with dexamethasone and thalidomide, as induction therapy prior to high-dose chemotherapy with autologous stem cell transplantation. The IFM 2005-01 and GIMEMA trials established bortezomib-based induction as a standard of care.
- Progressive multiple myeloma: In combination with pegylated liposomal doxorubicin or dexamethasone for adult patients who have received at least one prior therapy. The DOXIL-MMY-3001 trial demonstrated the benefit of the bortezomib-doxorubicin combination.
- Relapsed or refractory multiple myeloma: As monotherapy or in combination with other agents for patients who have progressed after prior treatment. The APEX trial established single-agent bortezomib as superior to high-dose dexamethasone in relapsed myeloma.
- Mantle cell lymphoma: In combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) for previously untreated adult patients who are not suitable for haematopoietic stem cell transplantation. The LYM-3002 trial demonstrated significantly improved progression-free survival for VR-CAP versus R-CHOP.
Multiple myeloma is a cancer of the plasma cells in the bone marrow. Plasma cells are a type of white blood cell that normally produces antibodies to fight infection. In myeloma, abnormal plasma cells multiply uncontrollably, crowding out normal blood-forming cells in the marrow and producing large amounts of a single type of abnormal antibody (called M-protein or paraprotein). This leads to bone destruction, kidney damage, anemia, immune deficiency, and other serious complications. Multiple myeloma accounts for approximately 10% of all blood cancers and primarily affects older adults, with a median age at diagnosis of 70 years.
Mantle cell lymphoma is a relatively rare but aggressive type of non-Hodgkin lymphoma that arises from B lymphocytes in the mantle zone of lymph nodes. It is characterized by the translocation t(11;14) and overexpression of cyclin D1, and typically presents at an advanced stage with widespread lymph node involvement, spleen enlargement, and frequent bone marrow and gastrointestinal tract involvement. Mantle cell lymphoma accounts for approximately 5-7% of all non-Hodgkin lymphomas.
The proteasome is often described as the cell's recycling center. It breaks down proteins that are damaged, misfolded, or no longer needed, allowing their building blocks (amino acids) to be reused. Cancer cells, especially myeloma cells, are unusually dependent on the proteasome because they produce proteins at a very high rate. Blocking the proteasome with bortezomib overwhelms the cancer cell's ability to handle protein waste, leading to a toxic buildup that triggers cell death. Normal cells are also affected but are generally more resilient because they have lower rates of protein production and additional backup systems for managing protein stress.
What Should You Know Before Taking Bortezomib Fresenius Kabi?
Contraindications
There are specific situations in which Bortezomib Fresenius Kabi must not be used. Understanding these contraindications is essential for safe treatment.
- Hypersensitivity: Do not receive Bortezomib Fresenius Kabi if you are allergic (hypersensitive) to bortezomib, boron, or mannitol. Hypersensitivity reactions, including rare cases of anaphylaxis, have been reported. If you have had an allergic reaction to any proteasome inhibitor, inform your doctor.
- Acute diffuse infiltrative pulmonary disease: Bortezomib must not be given as intrathecal (into the spinal fluid) injection. Cases of fatal outcomes have been reported following inadvertent intrathecal administration.
- Severe hepatic impairment: Patients with moderate to severe hepatic impairment require dose reduction and careful monitoring. The safety of full-dose bortezomib in this population has not been established.
Warnings and Precautions
Peripheral neuropathy is one of the most common and clinically significant side effects of bortezomib. It presents as numbness, tingling, burning pain, or weakness in the hands and feet. The risk increases with cumulative doses. Report any new neurological symptoms to your doctor immediately, as prompt dose modification can prevent progression to more severe, potentially irreversible neuropathy. Subcutaneous administration is associated with significantly less neuropathy than intravenous dosing.
Before and during treatment with Bortezomib Fresenius Kabi, inform your doctor if any of the following apply to you:
- Thrombocytopenia: Bortezomib commonly causes a reduction in platelet counts, typically following a cyclical pattern with the nadir occurring around day 11 of each treatment cycle and recovery by the start of the next cycle. Platelet counts are monitored regularly, and dose adjustments or platelet transfusions may be necessary. The risk of bleeding is increased during periods of low platelet counts.
- Gastrointestinal toxicity: Nausea, vomiting, diarrhea, and constipation are common. In rare cases, serious complications such as paralytic ileus (loss of intestinal muscle activity) have been reported. Tell your doctor immediately about severe or persistent gastrointestinal symptoms.
- Herpes zoster reactivation: Bortezomib treatment significantly increases the risk of shingles (herpes zoster). Antiviral prophylaxis with aciclovir or valaciclovir is strongly recommended for all patients and should continue throughout treatment. Tell your doctor immediately if you develop a painful, blistering skin rash.
- Hepatotoxicity: Cases of liver injury, including acute liver failure, have been reported rarely. Liver function tests should be monitored regularly, particularly in patients with pre-existing liver disease or those taking other hepatotoxic medications.
- Hypotension: Orthostatic hypotension (a drop in blood pressure when standing up) and postural dizziness are common. Patients on antihypertensive medications may need dose adjustments. Stay well-hydrated and rise slowly from sitting or lying positions.
- Cardiac disorders: Cases of heart failure, decreased ejection fraction, and QT prolongation have been reported. Patients with existing heart disease or risk factors for cardiac problems require careful monitoring. Report any new shortness of breath, swelling of the ankles, or chest pain.
- Pulmonary toxicity: Rare cases of acute respiratory distress syndrome (ARDS), pneumonitis, and interstitial lung disease have been reported. Report any new or worsening breathing difficulties or cough immediately.
- Posterior reversible encephalopathy syndrome (PRES): This rare neurological condition can cause seizures, headache, confusion, visual disturbances, and high blood pressure. PRES is generally reversible if recognized and treated promptly, but treatment with bortezomib should be discontinued.
- Tumor lysis syndrome: Rapid destruction of cancer cells can lead to metabolic disturbances including high levels of uric acid, potassium, and phosphate in the blood. This is more likely in patients with high tumor burden. Adequate hydration and monitoring of electrolytes are important.
- Infections: Bortezomib suppresses the immune system and increases susceptibility to infections, including bacterial, viral, and fungal infections. Patients with neutropenia (low white blood cell counts) are at particular risk. Report any signs of infection such as fever, chills, or sore throat promptly.
Pregnancy and Breastfeeding
Bortezomib Fresenius Kabi should not be used during pregnancy. Animal studies have shown embryo-fetal toxicity at doses similar to those used in humans. There is insufficient data on the use of bortezomib in pregnant women, and the potential risk to the fetus is considered significant based on the drug's mechanism of action, which interferes with fundamental cellular processes essential for embryonic development.
Women of childbearing potential must use effective contraception during treatment and for at least three months after the last dose. If pregnancy occurs during treatment, the patient should be informed of the potential risks to the fetus. Men receiving bortezomib should also use effective contraception during and for three months following treatment, as the drug may affect sperm quality.
It is not known whether bortezomib is excreted in human breast milk. Due to the potential for serious adverse effects in nursing infants, breastfeeding must be discontinued during treatment with Bortezomib Fresenius Kabi. A decision should be made whether to discontinue breastfeeding or to discontinue treatment, taking into account the importance of the drug to the mother.
Bortezomib may impair fertility in both men and women. Animal studies have shown effects on male and female reproductive organs. Patients who wish to have children in the future should discuss fertility preservation options with their healthcare team before starting treatment.
How Does Bortezomib Fresenius Kabi Interact with Other Drugs?
Drug interactions with bortezomib can be complex and clinically significant. Because bortezomib is metabolized through the cytochrome P450 enzyme system, particularly CYP3A4, CYP2C19, and CYP1A2, other drugs that inhibit or induce these enzymes can alter bortezomib concentrations in the blood. Additionally, the pharmacodynamic effects of bortezomib on platelets, nerves, and immune function can be additive with other drugs that share these properties. Always inform your doctor about all medications, supplements, and herbal products you are taking.
Major Interactions
| Interacting Drug | Effect | Recommendation |
|---|---|---|
| Ketoconazole (strong CYP3A4 inhibitor) | Increases bortezomib exposure by approximately 35% | Use with caution; monitor closely for toxicity |
| Rifampicin (strong CYP3A4 inducer) | Decreases bortezomib exposure by approximately 45% | Avoid concurrent use; may reduce efficacy significantly |
| Oral antidiabetic agents | Unpredictable changes in blood glucose levels (hypo- or hyperglycemia) | Frequent blood glucose monitoring; dose adjustment may be needed |
| Oral anticoagulants (e.g., warfarin) | Altered INR values due to thrombocytopenia and liver enzyme effects | Frequent INR monitoring; dose adjustments may be required |
Minor Interactions
| Interacting Drug | Effect | Recommendation |
|---|---|---|
| Dexamethasone | Mild CYP3A4 induction; commonly used in combination | Standard combination; no dose adjustment needed |
| Omeprazole (CYP2C19 inhibitor) | Theoretical increase in bortezomib levels (CYP2C19 inhibition) | Generally safe; monitor for unusual side effects |
| Green tea extract | Preclinical evidence suggests possible reduced bortezomib efficacy | Avoid high-dose green tea supplements during treatment |
| Antihypertensives | Additive hypotensive effect with bortezomib-induced orthostatic hypotension | Monitor blood pressure; may need dose adjustments |
It is important to note that bortezomib is often administered as part of combination chemotherapy regimens. Common combinations include bortezomib with dexamethasone (VD), bortezomib with melphalan and prednisone (VMP), bortezomib with lenalidomide and dexamethasone (VRd), and bortezomib with cyclophosphamide and dexamethasone (VCD). These combinations have been extensively studied in clinical trials and have established safety and dosing guidelines. Your oncologist will carefully select the appropriate combination and monitor for overlapping toxicities.
Patients should avoid taking St. John's wort (Hypericum perforatum) during bortezomib treatment, as this herbal supplement is a potent CYP3A4 inducer that could significantly reduce bortezomib blood levels and compromise treatment efficacy. Similarly, grapefruit and grapefruit juice, which are CYP3A4 inhibitors, should be consumed with caution, although the clinical significance of this interaction with bortezomib is likely modest due to the drug's parenteral route of administration.
What Is the Correct Dosage of Bortezomib Fresenius Kabi?
Bortezomib Fresenius Kabi must only be prescribed and administered by a physician experienced in the use of anticancer drugs. The dosage is calculated based on your body surface area (BSA), which is determined from your height and weight. The powder must be reconstituted before injection: with sodium chloride 0.9% for intravenous use, or with sodium chloride 0.9% for subcutaneous use (at a different concentration). The reconstitution concentration differs depending on the route of administration, and errors in reconstitution can lead to overdose.
Adults
Standard Dosing (All Indications)
The recommended starting dose is 1.3 mg/m² body surface area per injection. The route can be either subcutaneous or intravenous (as a 3-5 second bolus injection).
| Indication | Regimen | Schedule | Cycles |
|---|---|---|---|
| Untreated myeloma (non-transplant) | VMP (bortezomib + melphalan + prednisone) | Twice weekly (days 1, 4, 8, 11) in cycles 1-4, then weekly (days 1, 8, 22, 29) in cycles 5-9 | 9 cycles of 6 weeks each |
| Untreated myeloma (transplant-eligible) | VD induction (bortezomib + dexamethasone) | Twice weekly (days 1, 4, 8, 11) of a 21-day cycle | 4 cycles before transplant |
| Relapsed/refractory myeloma | Bortezomib monotherapy or combinations | Twice weekly (days 1, 4, 8, 11) of a 21-day cycle | Up to 8 cycles; can extend to weekly if responding |
| Mantle cell lymphoma | VR-CAP (bortezomib + rituximab + CHP) | Twice weekly (days 1, 4, 8, 11) of a 21-day cycle | 6 cycles (maximum 8) |
Children and Adolescents
The safety and efficacy of Bortezomib Fresenius Kabi in children and adolescents below 18 years of age have not been established. There are no data available for the use of bortezomib in the pediatric population for its approved indications (multiple myeloma and mantle cell lymphoma). Therefore, bortezomib should not be used in patients under 18 years of age for these indications.
Elderly Patients
No initial dose adjustment is recommended for elderly patients with multiple myeloma or mantle cell lymphoma. However, elderly patients may be more susceptible to certain side effects, particularly peripheral neuropathy, thrombocytopenia, gastrointestinal toxicity, and fatigue. In the VMP regimen specifically, the twice-weekly schedule in the first four cycles is followed by a once-weekly schedule in subsequent cycles, which helps improve tolerability in the typically older patient population treated with this regimen. Close monitoring is essential, and dose modifications should be implemented promptly if significant toxicity occurs. Patients aged 75 years and older may experience higher rates of grade 3 or higher adverse events.
Missed Dose
If a dose of bortezomib is missed, it should generally not be made up by doubling the next dose. The treatment schedule should be adjusted so that there is at least 72 hours between consecutive doses when administered twice weekly, or at least 72 hours between doses when administered once weekly. If a dose is missed, contact your healthcare team to determine the most appropriate course of action for your specific treatment schedule. Maintaining consistent dosing intervals is important for optimizing both efficacy and safety.
Overdose
There is no specific antidote for bortezomib overdose. Overdose may cause severe, symptomatic hypotension, acute heart failure, thrombocytopenia, and severe peripheral neuropathy. Cases of fatal cardiac and respiratory failure have been reported in patients who received more than twice the recommended dose. In the event of overdose, vital signs should be monitored closely, and appropriate supportive measures should be instituted to maintain blood pressure, body temperature, and fluid balance. Treatment is supportive and symptomatic.
Bortezomib must be reconstituted at the correct concentration for the intended route of administration. The concentration for subcutaneous injection (2.5 mg/mL) is different from that for intravenous injection (1 mg/mL). Errors in reconstitution can lead to either overdose or underdose. Only experienced healthcare professionals should prepare and administer this medication. Always verify the route of administration before injection.
What Are the Side Effects of Bortezomib Fresenius Kabi?
Like all medicines, Bortezomib Fresenius Kabi can cause side effects, although not everybody gets them. Some of these side effects may be serious. The frequency and severity of side effects can vary depending on the dose, schedule, route of administration, and whether bortezomib is given alone or in combination with other medications. Your healthcare team will monitor you closely and can adjust treatment to manage side effects effectively.
Tell your doctor immediately if you experience any of the following during or after treatment: difficulty breathing, dizziness, fainting, skin rash, facial swelling, new or worsening numbness or tingling in hands or feet, unusual bleeding or bruising, severe nausea or vomiting, dark or bloody stools, severe headache with visual disturbances, chest pain, or persistent fever.
Very Common Side Effects
May affect more than 1 in 10 people
- Thrombocytopenia (low platelet count)
- Neutropenia (low white blood cell count)
- Anemia (low red blood cell count)
- Peripheral neuropathy (numbness, tingling, pain in hands/feet)
- Nausea
- Diarrhea
- Constipation
- Vomiting
- Fatigue and general weakness
- Fever (pyrexia)
- Decreased appetite
- Headache
- Herpes zoster (shingles)
- Joint pain (arthralgia) and muscle pain (myalgia)
Common Side Effects
May affect up to 1 in 10 people
- Orthostatic hypotension (drop in blood pressure when standing)
- Dizziness
- Rash and itching (pruritus)
- Abdominal pain
- Insomnia
- Upper respiratory tract infections
- Pneumonia
- Dehydration
- Peripheral edema (swelling)
- Blurred vision
- Injection site reactions (subcutaneous route)
- Dyspnea (shortness of breath)
- Weight loss
- Elevated liver enzymes
Uncommon Side Effects
May affect up to 1 in 100 people
- Heart failure
- Pulmonary hypertension
- Tumor lysis syndrome
- Posterior reversible encephalopathy syndrome (PRES)
- Autonomic neuropathy
- Severe skin reactions (Stevens-Johnson syndrome)
- Pericardial effusion
- Interstitial lung disease / pneumonitis
- Gastrointestinal hemorrhage
- Hepatitis and jaundice
Rare Side Effects
May affect up to 1 in 1,000 people
- Progressive multifocal leukoencephalopathy (PML)
- Acute respiratory distress syndrome (ARDS)
- Toxic epidermal necrolysis (TEN)
- Anaphylaxis
- Acute pancreatitis
- Optic neuropathy / optic neuritis
- Hearing loss (sensorineural)
- Paralytic ileus
Peripheral neuropathy deserves special attention because it is one of the most clinically significant side effects of bortezomib and can substantially affect quality of life. The neuropathy is predominantly sensory, presenting as numbness, tingling, burning pain, or loss of sensation in the feet and hands (in a "stocking-and-glove" distribution). Less commonly, motor neuropathy with weakness can occur. The risk increases with cumulative dose exposure, and the condition may be partially or fully reversible if the dose is reduced or treatment is discontinued promptly when symptoms appear. The subcutaneous route of administration has been demonstrated to significantly reduce the incidence and severity of peripheral neuropathy compared to intravenous injection, with an overall neuropathy rate of approximately 38% versus 53% in the pivotal MMY-3021 trial, and a grade 3 or higher neuropathy rate of 6% versus 16%.
Thrombocytopenia (low platelet count) is another hallmark side effect of bortezomib treatment. Unlike the thrombocytopenia caused by many other chemotherapy agents, bortezomib-induced thrombocytopenia follows a characteristic cyclical pattern. Platelet counts typically begin to decline after the first dose in each cycle, reach their lowest point (nadir) around days 11-14, and then recover to baseline or near-baseline levels before the start of the next cycle. This predictable pattern allows for appropriate monitoring and management, including platelet count checks before each dose and dose modifications or delays when counts fall below certain thresholds.
How Should You Store Bortezomib Fresenius Kabi?
Proper storage of Bortezomib Fresenius Kabi is essential to ensure the medication remains effective and safe for use. As this is a hospital-administered medication, storage is typically handled by your healthcare facility's pharmacy department. However, understanding the storage requirements helps ensure quality standards are maintained.
- Unopened vials: Store below 25°C (77°F). Do not freeze. Keep the vials in the original outer carton to protect from light.
- After reconstitution: The reconstituted solution should ideally be used immediately after preparation. If not used immediately, chemical and physical in-use stability has been demonstrated for up to 8 hours at 25°C in the original vial. The total storage time for the reconstituted medicinal product should not exceed 8 hours prior to administration.
- Appearance: The reconstituted solution should be clear and colorless. Do not use if the solution is discolored, cloudy, or contains visible particles.
- Disposal: This medicine is for single use only. Any unused medicine or waste material should be disposed of in accordance with local requirements for cytotoxic agents.
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date stated on the vial label and carton. The expiry date refers to the last day of that month. Your pharmacist or healthcare provider will check these details before each administration.
What Does Bortezomib Fresenius Kabi Contain?
Understanding the composition of Bortezomib Fresenius Kabi helps patients and healthcare professionals identify potential allergens and ensure proper preparation of the medication.
- Active substance: Each vial contains 1 mg of bortezomib (as a mannitol boronic ester). Bortezomib is a modified dipeptidyl boronic acid that forms a reversible complex with the threonine residue at the active site of the 26S proteasome.
- Other ingredient (excipient): Mannitol (E421). Mannitol serves as a bulking agent and also forms a boronic ester complex with bortezomib in the lyophilized formulation, which enhances stability.
The powder is white to off-white in appearance. After reconstitution with the appropriate volume of sodium chloride 0.9% solution, the resulting solution is clear and colorless, with a pH of approximately 4-7. For intravenous administration, 1 mg of bortezomib is reconstituted with 1 mL of sodium chloride 0.9% to give a final concentration of 1 mg/mL. For subcutaneous administration, 1 mg of bortezomib is reconstituted with 0.4 mL of sodium chloride 0.9% to give a final concentration of 2.5 mg/mL. It is critical that the correct reconstitution volume is used for the intended route of administration.
Bortezomib Fresenius Kabi is a biosimilar or generic version of the original bortezomib product. It contains the same active substance and has been demonstrated to be therapeutically equivalent through rigorous pharmaceutical quality and bioequivalence studies. The product is manufactured by Fresenius Kabi, a global healthcare company specializing in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition.
Frequently Asked Questions About Bortezomib Fresenius Kabi
Both routes deliver the same dose of bortezomib (1.3 mg/m²) and achieve similar clinical efficacy. The key difference is in side effects: subcutaneous (under the skin) injection is associated with significantly less peripheral neuropathy compared to intravenous (into the vein) injection. The MMY-3021 clinical trial showed that grade 3 or higher peripheral neuropathy occurred in only 6% of patients receiving subcutaneous bortezomib compared to 16% with intravenous administration. The subcutaneous route may cause local injection site reactions (redness, swelling, or itching at the injection site), which are generally mild and resolve on their own. Many oncologists now prefer the subcutaneous route as the standard approach.
The duration of treatment depends on the specific regimen, the indication, and how well you respond. For newly diagnosed multiple myeloma patients not undergoing transplant, the VMP regimen consists of 9 cycles (approximately 54 weeks). For transplant-eligible patients, bortezomib induction typically lasts 3-4 cycles (approximately 9-12 weeks) before transplant. For relapsed or refractory myeloma, treatment may continue for up to 8 or more cycles, depending on response and tolerability. Your oncologist will regularly assess your response using blood tests, bone marrow biopsies, and imaging to determine the optimal duration of treatment.
Bortezomib may cause fatigue, dizziness, fainting, blurred vision, and other symptoms that could impair your ability to drive or use machines safely. The effect varies between individuals. If you experience any of these symptoms, you should not drive or operate machinery until they resolve. Discuss your specific situation with your doctor, who can advise you based on your individual response to the treatment. It is important to be cautious, especially during the first few cycles of treatment when you are still learning how the medication affects you.
Bortezomib suppresses certain parts of the immune system, particularly the function of T lymphocytes that normally keep latent viruses in check. The varicella-zoster virus (which causes chickenpox and shingles) commonly reactivates in patients receiving bortezomib, with rates of herpes zoster reported in up to 13% of patients in clinical trials when no antiviral prophylaxis was given. Taking a preventive antiviral medication such as aciclovir or valaciclovir significantly reduces this risk. Your doctor will typically prescribe antiviral prophylaxis throughout your bortezomib treatment and possibly for a period after treatment ends.
Report any new or worsening numbness, tingling, burning, pain, or weakness in your hands or feet to your healthcare team as soon as possible. These symptoms may indicate peripheral neuropathy, a common but important side effect of bortezomib. Early recognition and dose adjustment are crucial because nerve damage can become permanent if treatment continues unchanged. Your doctor has established dose modification guidelines specifically for neuropathy: mild symptoms may lead to a dose reduction, moderate symptoms to a treatment pause until improvement, and severe symptoms may require discontinuation. Switching from intravenous to subcutaneous administration can also help reduce neuropathy.
Bortezomib Fresenius Kabi contains the same active ingredient (bortezomib) at the same strength (1 mg per vial) and in the same pharmaceutical form (powder for solution for injection) as the original bortezomib product. It has been approved by regulatory authorities based on comprehensive quality, safety, and efficacy data demonstrating therapeutic equivalence. The manufacturing processes meet the same rigorous pharmaceutical standards. Generic bortezomib products like Bortezomib Fresenius Kabi help improve access to this essential cancer treatment by providing a more cost-effective alternative while maintaining the same therapeutic benefit and safety profile.
References
- European Medicines Agency (EMA). Bortezomib Summary of Product Characteristics. Available from: www.ema.europa.eu. Accessed January 2026.
- San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma (VISTA trial). N Engl J Med. 2008;359(9):906-917.
- Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma (MMY-3021): a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431-440.
- Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma (APEX trial). N Engl J Med. 2005;352(24):2487-2498.
- Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma (LYM-3002). N Engl J Med. 2015;372(10):944-953.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 2.2025.
- Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines. Ann Oncol. 2024;35(5):446-462.
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd List (2023). Bortezomib listed as an essential antineoplastic agent.
- International Myeloma Working Group (IMWG). Updated criteria for the diagnosis and management of multiple myeloma. Lancet Oncol. 2024.
- Rajkumar SV, Kumar S. Multiple myeloma: current treatment algorithms. Blood Cancer J. 2024;14:e456.
Editorial Team
This article has been written and reviewed by licensed medical professionals with expertise in oncology, hematology, and clinical pharmacology.
iMedic Medical Editorial Team
Specialists in Oncology and Clinical Pharmacology
iMedic Medical Review Board
Independent expert review according to WHO, EMA, FDA, and NCCN guidelines
All medical content on iMedic is independently produced with no pharmaceutical company sponsorship or advertising. Our editorial process follows the GRADE evidence framework, and all claims are supported by peer-reviewed research and international clinical guidelines. For questions about our editorial process, visit our Editorial Standards page.